CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer

Shanghai Jiao Tong University

Status: Enrolling

Conditions: Breast Cancer

Treatments: Drug: CDK4/6 inhibitor

Study type: Observational

Funder types: Other

Identifiers

NCT05795335

KY2022-097-B

Details and patient eligibility

About

This is an ambispective, single-center study to evaluate the survival outcomes, adverse events and predictive biomarkers for CDK4/6 inhibitors in patients with hormone receptor-positive advanced breast cancer.

Enrollment: 172 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Aged ≥18 and older
• Confirmed diagnosis of hormone receptor-positive breast cancer.
• Subjects with locoregionally recurrent or metastatic disease not amenable to curative therapy.
• Subjects have received or plan to receive CDK4/6 inhibitors for advanced disease.
• ECOG 0-2
• Adequate organ function

Exclusion criteria

• Subjects disable to swallow pills.
• History of immunodeficiency disease

Trial design

172 participants in 1 patient group

Patients have received or plan to receive CDK4/6 inhibitors for advanced disease.

Treatment:

Drug: CDK4/6 inhibitor